Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Regeneron (REGN)

Tipranks - Tipranks - Fri Apr 10, 6:12AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND) and Regeneron (REGN).

Easter Sale - 70% Off TipRanks

Ascendis Pharma (ASND)

In a report released yesterday, Paul Choi from Goldman Sachs maintained a Buy rating on Ascendis Pharma, with a price target of $255.00. The company’s shares closed last Wednesday at $233.20.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 7.7% and a 52.6% success rate. Choi covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Soleno Therapeutics, and BridgeBio Pharma. ;'>

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $293.77, which is a 32.8% upside from current levels. In a report issued on April 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $300.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Regeneron (REGN)

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Regeneron today and set a price target of $825.00. The company’s shares closed last Wednesday at $775.53.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.2% and a 55.6% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regeneron with a $871.91 average price target, representing a 13.9% upside. In a report issued on April 7, RBC Capital also maintained a Hold rating on the stock with a $779.00 price target.

Read More on ASND:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).